Clinical trials: Circulatory Failure (Shock)
Sepsis, Septic Shock
Predictive algoRithm for EValuation and Intervention in SEpsis
In this prospective study, the ability of a machine learning algorithm to predict sepsis and influence clinical outcomes, will be investigated at Cabell Huntington Hospital (CHH).
- Conditions
- Sepsis, Septic Shock, Severe Sepsis
- Trial name
- PREVISE (NCT03235193)
- Testing
- Severe Sepsis Prediction, Severe Sepsis Detection
- Where
- United States
- Volunteers
- 2,296 people
- Sponsor
- Dascena
Hypovolemic Shock
Efficacy of PMZ-2010 (Centhaquine) a Resuscitative Agent for Hypovolemic Shock
This is a prospective, multi-centric, randomized, double-blind, parallel, controlled phase-III efficacy clinical study of PMZ-2010 therapy in patients with hypovolemic shock.
- Trial name
- NCT04045327
- Testing
- Normal saline + Standard Treatment, Centhaquine + Standard Treatment
- Where
- 18 sites in India
- Volunteers
- 105 people
- Sponsor
- Pharmazz, Inc.
SARS-CoV2 Infection
Efficacy and Safety of EXOSOME-MSC Therapy to Reduce Hyper-inflammation In Moderate COVID-19 Patients
In COVID-19 infection caused by the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there is a dysregulation of the immune system response that causes cytokine storm syndrome.
- Trial name
- EXOMSC-COV19 (NCT05216562)
- Testing
- Exosome-MSC Intravenous injection, COVID-19 Standard Treatment
- Where
- 3 sites in Indonesia
- Volunteers
- 60 people
- Sponsor
- Dermama Bioteknologi Laboratorium
Sepsis, Multiple Organ Dysfunction Syndrome
Bovine Intestinal Alkaline Phosphatase for the Treatment of Patients With Sepsis
Eligible patients will receive either AP or matching placebo in a double blind, randomized design and following a 2:1 ratio. All medication will be given in addition to standard care for sepsis patients.
- Trial name
- NCT00430859
- Testing
- Alkaline Phosphatase
- Where
- 10 sites in Belgium, Netherlands
- Volunteers
- 37 people
- Sponsor
- AM-Pharma
Severe Sepsis
AZD9773 Dose Escalation Study
This is a double-blind, placebo-controlled, multi-center, dose-escalation study to assess the safety, tolerability, Pharmacokinetics and Pharmacodynamics of single and multiple ascending intravenous infusions of CytoFab (AZD9773)…
- Trial name
- NCT00615017
- Testing
- AZD9773 (CytoFab)
- Where
- 26 sites in United States
- Volunteers
- 70 people
- Sponsor
- AstraZeneca
Severe Sepsis, Septic Shock
Procalcitonin Monitoring Sepsis Study
The purpose of this study is to investigate the relationship between a procalcitonin decrease over 72 hours and outcome in patients who have severe sepsis or septic shock.
- Trial name
- MOSES (NCT01523717)
- Where
- 13 sites in United States
- Volunteers
- 858 people
- Sponsor
- Brahms AG
Sepsis, Septic Shock
Multicenter Symphony IL-6 Monitoring Sepsis ICU Study
The primary objective of this study is to establish an IL-6 concentration cutoff and optimal time point(s) for using Symphony IL-6 that predict 28-day mortality in patients who are admitted or are intended to be admitted to the…
- Trial name
- SYMON (NCT06181604)
- Where
- 7 sites in United States
- Volunteers
- 143 people
- Sponsor
- Bluejay Diagnostics, Inc.
Catecholamine-resistant Hypotension (CRH), Distributive Shock
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
This is a Phase 3, double-blind, randomized study of LJPC-501 (angiotensin II) in adult patients diagnosed with catecholamine-resistant hypotension (CRH) conducted in multiple centers globally.
- Conditions
- Catecholamine-resistant Hypotension (CRH), Distributive Shock, High Output Shock, Sepsis
- Trial name
- ATHOS-3 (NCT02338843)
- Testing
- LJPC-501
- Where
- 115 sites in United States, Australia and 8 more
- Volunteers
- 344 people
- Sponsor
- La Jolla Pharmaceutical Company
Shock, Hemorrhagic, Shock, Traumatic
Phase IIa Study of MP4OX in Traumatic Hemorrhagic Shock Patients
MP4OX is a novel oxygen therapeutic agent specifically developed to perfuse and oxygenate tissue at risk for ischemia and hypoxia.
- Conditions
- Shock, Hemorrhagic, Shock, Traumatic, Acidosis, Lactic
- Trial name
- NCT01004198
- Testing
- MP4OX, Ringers Lactate solution
- Where
- 13 sites in France, Germany and 2 more
- Volunteers
- 51 people
- Sponsor
- Sangart
Covid19, Pneumonia
Anakinra in the Management of COVID-19 Infection
Coronavirus Disease 2019 (COVID-19) was first isolated in Wuhan, China in December 2019. It is rapidly spreading worldwide, posing a severe threat to global health.
- Conditions
- Covid19, Pneumonia, Cytokine Release Syndrome, Corona Virus Infection
- Trial name
- NCT04643678
- Testing
- Anakinra, Standard of Care
- Where
- Qatar
- Volunteers
- 80 people
- Sponsor
- Hamad Medical Corporation
Cardiogenic Shock
Catheter-Oriented Unloading and Recovery With a Left Ventricular Assist Gear: Efficacy in Post Cardiotomy Cardiogenic Shock
This study is a prospective, multicenter, single-arm clinical trial conducted in China to evaluate the efficacy and safety of a novel left ventricular assist device, SynFlow Duro system, manufactured by ForQaly Medical in the…
- Trial name
- COURAGE (NCT07560085)
- Testing
- SynFlow Duro
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- ForQaly Medical (Shanghai) Co., Ltd
Acute Pancreatitis, Systemic Inflammatory Response Syndrome
CM4620 Injectable Emulsion Versus Supportive Care in Patients With Acute Pancreatitis and SIRS
This open-label, dose-response study will evaluate the safety and efficacy of CM4620-IE in patients with acute pancreatitis and accompanying SIRS. The study will consist of two phases.
- Trial name
- NCT03401190
- Testing
- CM4620 Injectable Emulsion (Low Dose), CM4620 Injectable Emulsion (High Dose)
- Where
- 9 sites in United States
- Volunteers
- 21 people
- Sponsor
- CalciMedica, Inc.
Cardiogenic Shock
Randomized Evaluation of Istaroxime for Stabilization in Acute Heart Failure-Cardiogenic Shock
The goal of this clinical trial is to learn if the drug istaroxime works to treat cardiogenic shock due to acute heart failure in adults. It will also learn about the safety of istaroxime.
- Trial name
- RESCUE HF-CS (NCT07583446)
- Testing
- istaroxime
- Where
- Armenia
- Volunteers
- 600 people
- Sponsor
- Seismic Pharmaceuticals Operations LLC
Covid19, ARDS
Expanded Access for Use of bmMSC-Derived Extracellular Vesicles in Patients With COVID-19 Associated ARDS
ExoFlo, Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Allograft Product, Infusion Treatment is currently being studied in Protocol DB-EF-PhaseIII-0001 in patients COVID-19 associated moderate to severe acute…
- Conditions
- Covid19, ARDS, Hypoxia, Cytokine Storm
- Trial name
- NCT04657458
- Testing
- ExoFlo
- Sponsor
- Direct Biologics, LLC
Cardiogenic Shock, Extracorporeal Membrane Oxygenation Complication
Efficacy and Clinical Outcomes of Levosimendan in E-CPR
Treatment of refractory cardiac arrest requiring cardiopulmonary resuscitation (CPR) may be augmented with Extracorporeal membrane oxygenation (ECMO) to re-establish perfusion in the absence of return of spontaneous circulation.
- Trial name
- ECPR (NCT05730907)
- Testing
- Levosimendan
- Where
- Qatar
- Volunteers
- 100 people
- Sponsor
- Hamad Medical Corporation
Percutaneous Large Hole Vascular Closure
PerQseal® Impella Early Feasibility Study
The purpose of this Clinical Investigation Plan is to assess the initial feasibility results of the PerQseal® device, when used on this very specific Impella population.
- Trial name
- NCT04818541
- Testing
- PPCI, Cardiogenic shock
- Where
- 4 sites in United States
- Volunteers
- 19 people
- Sponsor
- Vivasure Medical Limited
Sepsis, Acute Infection
A Multicenter Prospective Observational Study to Derive and Verify the Performance of a Host-response Based Diagnostic Tool for Early Detection of Severe Infections.
The study is a multi-center, prospective, observational clinical study enrolling patients from at least 3 medical centers. Study population will include patients over the age of 18 years.
- Trial name
- NCT06665542
- Where
- 8 sites in United States, Israel
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- MeMed Diagnostics Ltd.
Septic Shock
Effect of Early Administration of Albumin 20% Versus Crystalloid
Sepsis and septic shock are global health problems, leading to a high mortality rate. They are often associated with extremely low blood pressure and multiple organ dysfunctions, which are the main causes of death in critically…
- Trial name
- NCT06370078
- Testing
- Albumin Human
- Where
- Egypt
- Volunteers
- 46 people
- Sponsor
- Egymedicalpedia
Sepsis, Septic Shock
Combined Hemoperfusion and Therapeutic Plasma Exchange for Treatment of Patients With Septic Shock
Sepsis is a critical burden for a healthcare. From 2000 to 2020, the number of publications and clinical studies on the topic of Sepsis and septic shock on the National Library of Medicine resource The National Center for…
- Trial name
- NCT06404424
- Testing
- Efferon LPS, Efferon CT
- Where
- Russia
- Volunteers
- 82 people
- Sponsor
- Efferon JSC
Erectile Dysfunction, Sexual Dysfunction, Physiological
ARIES for Vasculogenic Erectile Dysfunction
This study aims to evaluate the safety and efficacy of low-intensity extracorporeal shock wave therapy utilizing the Dornier Aries in the treatment of erectile dysfunction of vasculogenic origin.
- Trial name
- AriesIDE#1 (NCT02620982)
- Testing
- ARIES (Extracorporal Shock Wave Application)
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Dornier MedTech Systems